Ocugen’s Valuation Deserves a Haircut, Says Analyst

Ocugen (OCGN) has been a 2021 success story, as the eye disease specialist has decided to moonlight in the lucrative world of coronavirus stocks.

The company has inked a deal with Bharat Biotech to bring the India-based company’s Covid-19 vaccine Covaxin to the U.S. It’s a gamble that has paid off handsomely so far, particularly in the stock market’s eyes; even after pulling back since the beginning of May, the stock’s year-to-date performance shows gains in the 455% ballpark.

Does the rally have more legs? According to Chardan analyst Keay Nakae, the stock might have used up all the fuel in the tank already.

Nakae’s skeptical analysis follows on from Ocugen’s recent quarterly report. Being a pre-revenue company, the bottom-and top-line results are of less importance. More pertinently, investors wanted to get an update regarding Covaxin’s progress, and right now, the company’s target of getting the FDA to issue an EUA for Covaxin has stalled (Covaxin has already been granted an EUA in India).

Ocugen has commenced discussions with the regulatory body, and a Master File containing vital information and data to date (including preclinical studies, CMC, and clinical studies) has already been submitted. However, there has been a delay in obtaining additional data from Bharat that is required to complete the EUA submission, due to the current surge in COVID-19 cases in India.

And according to Nakae, time is running out.

“The Covid-19 vaccine landscape in the U.S. remains fast changing, moving in a direction that we believe is reducing the potential market advantages that COVAXIN may offer,” the 5-star analyst said. “Compared to just a month ago, the U.S. is no longer supply-constrained.”

Moreover, in their respective development efforts to combat emerging variants and show their vaccines are suitable to younger patients, both Moderna and Pfizer-BioNTech are making progress.

These are issues which need to be considered when mulling an investment in OCGN, says Nakae, who concludes, “We believe that investors should weigh these developments against the attractive features of COVAXIN’s inactivated intact virion design…”

Ultimately, Nakae’s advice is to say on the sidelines. The analyst reiterates a Neutral (i.e. Hold) rating for the shares, while reducing the price target from $13 to $8. The reduced figure implies ~23% downside from current levels. (To watch Nakae’s track record, click here)

Looking at the consensus breakdown, analysts are split right down the middle when it comes to OCGN. 2 Buys vs 2 Holds lend itself to a ‘Moderate Buy’ Street consensus. With an average price target of $10.25, the analysts think OCGN is liable to remain range-bound for now.

To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.


RSS Latest Press Release

  • Confort Prestige | Climatisation & Chauffage Announces HVAC Services For Improved Energy Efficiency
    TERREBONNE, QUEBEC- NOVEMBER 14, 2021- Premier heating and cooling company Confort Prestige is excited to share HVAC solutions with domestic customers in the Terrebonne area. These services aim to save customers money on their heating and cooling expenses throughout the year.   Since its debut, Confort Prestige has been committed to customer service. This starts […]
  • Hundreds of Car and Truck Parts Available from Salvage Specialist
    Morganville, NJ – When it comes to finding an auto part for a foreign or domestic vehicle, Trilenium Auto Salvage usually has the answer.   The Morganville, NJ salvage specialist has hundreds, if not thousands, of parts and components at its Tennent Rd premises available.   Trilenium Auto Salvage is one of the busiest salvage specialists […]
  • Flowsent Weed Delivery Offers the Fastest Weed Delivery Service in the Bay Area
    Bay Area, CA - As it becomes easier to get cannabis in different stores and online, weed delivery in Oakland, San Francisco, and other Bay Area cities are becoming more common. People are looking for the easiest way to get their hands on high-quality, safe cannabis, and nothing beats direct to your door.    Many […]
  • Cannamazoo Now Offering the Top Cannabis Concentrates in Michigan
    What are Cannabis Concentrates, Oils, and Extracts?   Kalamazoo, MI - You may be familiar with recreational cannabis in its usual form, but have you ever tried extracts, oils, and concentrates? Each of these forms offers unique effects and benefits that smoking cannabis flowers can't provide. Simple dosing, cleaner effects, and better taste are just […]